Natalia Rodon¹, Ruth Roman¹, Montse Verdu^1,3 ,Miquel Calvo⁴, Beatriz Garcia-Pelaez¹, Marta Gonzalez¹, Carme Pubill³ i Xavier Puig^1,2,3.

¹BIOPAT. Biopatologia Molecular SL, Grup Assistència. ²Hospital de Barcelona-SCIAS, Grup Assistencia. ³Histopat Laboratoris. ⁴Departament d’Estadística, Facultat de Biologia. UB. Barcelona. 

INTRODUCCIÓ I OBJECTIU

Les mutacions de l’oncogen KRAS, presents al 30-50% dels carcinomes colorectals, expliquen la manca de resposta a inhibidors dels receptors EGF. L’objectiu de l’estudi és confirmar, mitjançant un estudi multivariant, les correlacions observades en un estudi univariant inicial entre l’estat mutacional de KRAS […]

Natalia Rodon¹, Ruth Roman¹, Montse Verdu^1,3 ,Miquel Calvo⁴, Beatriz Garcia-Pelaez¹, Marta Gonzalez¹, Carme Pubill³ and Xavier Puig^1,2,3.

¹BIOPAT. Biopatologia Molecular SL, Grup Assistència. ²Hospital de Barcelona-SCIAS, Grup Assistencia. ³Histopat Laboratoris. ⁴Departament d’Estadística, Facultat de Biologia. UB. Barcelona.

KRAS oncogenic mutations, present in approximately 30-50% of colorectal carcinomas (CRC), result in a lack of response to EGFR inhibitors. The aim of this study was to confirm with a multivariate analysis the correlations observed in our initial univariate approach between KRAS mutational status and […]

M Verdu^1,3, R Roman¹, M Calvo⁴, N Rodon¹, B Garcia¹, M Gonzalez¹ and X Puig^1,2,3.

¹BIOPAT.Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain; ²Hospital de Barcelona, SCIAS, Grup Assistència, Barcelona, Spain; ³Histopat Laboratoris, Barcelona, Spain and ⁴Statistics Department, Universitat Barcelona, Barcelona, Spain.

Background: Micropapillary carcinoma (MC) is accepted as an aggressive variant of colorectal adenocarcinoma, described for the first time in the breast and later in other organs. At present, there are a limited number of colorectal MC series reported, not enough to define […]

Natalia Rodón¹, Ruth Román¹, Montse Verdú^1,3, Miquel Calvo⁴, Beatriz García-Peláez¹, Marta González¹, Carme Pubill³ y Xavier Puig^1,2,3.

¹BIOPAT. Biopatologia Molecular, SL, Grup Assistència; ²Hospital de Barcelona-SCIAS, Grup Assistència; ³Histopat Laboratoris; ⁴Departament d’Estadística, Universitat de Barcelona. Barcelona

Background:

KRAS mutations, present in approximately 30-50% of colorectal carcinomas (CRC) has been recently associated with lack of response to anti-EGFR therapy, poor prognosis and high mitotic activity. Nevertheless, its relation to other histopathological and molecular parameters has not been well established.

Our first approach was to determine […]